Adipocyte DIO2 Expression Increases in Human Obesity but Is Not Related to Systemic Insulin Sensitivity
Table 1
Demographics and clinical characteristics of lean and obese patients.
Lean subjects ()
Obese subjects with VAT biopsies ()
Obese subjects with SAT biopsies ()
Number of females/number of males (% female)
6/15 (29)
60/13 (82)
27/8 (77)
Age (years)
47.8 ± 11.6
44.8 ± 11.9
43.3 ± 11.2
BMI (kg/m2)
23.3 ± 1.5
46.7 ± 11.0
48.0 ± 8.5
Fasting glucose (mg/dL)
85.0 ± 13.8
93.4 ± 22.3
90.9 ± 20.4
Fasting insulin (μIU/mL)
5.2 ± 5.3
18.8 ± 16.8
17.3 ± 11.2
HOMA-IR score
1.1 ± 1.0
4.7 ± 4.7
4.1 ± 3.1
HOMA-β score
87.5 ± 167.1
236.0 ± 193.8
243.3 ± 203.9
Plasma adiponectin (ng/mL)
11,294 ± 8448
6453 ± 3723
6380.3644
Plasma leptin (ng/mL)
26.9 ± 11.3
47.8 ± 31.9
55.4 ± 40.7
Values are means ± SD. BMI: body mass index; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of beta-cell function. Value significantly different from the lean value ().
